KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) FCF Margin (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of FCF Margin data on record, last reported at 18.57% in Q4 2025.

  • For Q4 2025, FCF Margin fell 3395.0% year-over-year to 18.57%; the TTM value through Dec 2025 reached 9.84%, down 657.0%, while the annual FY2025 figure was 9.81%, 660.0% down from the prior year.
  • FCF Margin reached 18.57% in Q4 2025 per ACAD's latest filing, down from 26.52% in the prior quarter.
  • Across five years, FCF Margin topped out at 36.96% in Q4 2023 and bottomed at 66.1% in Q1 2022.
  • Average FCF Margin over 5 years is 4.98%, with a median of 5.15% recorded in 2022.
  • Peak YoY movement for FCF Margin: skyrocketed 5444bps in 2023, then crashed -3395bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 17.68% in 2021, then grew by 1bps to 17.48% in 2022, then skyrocketed by 311bps to 36.96% in 2023, then plummeted by -58bps to 15.38% in 2024, then crashed by -221bps to 18.57% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 18.57% in Q4 2025, 26.52% in Q3 2025, and 24.17% in Q2 2025.